Latest Key Developments (Source: Significant Developments)

Active Biotech Ab : Annual general meeting of active biotech ab . In accordance with board of directors' proposal, it was resolved that no dividend would be paid .Board members and managing director were discharged from liability with respect to their management of company for 2015.
Full Article

Active Biotech AB:Plans to develop tasquinimod for the treatment of multiple myeloma.Says patent application for the treatment of multiple myeloma with the company's compound tasquinimod will be public within short.Says with this application, treatment of multiple myeloma with tasquinimod is potentially protected until 2035.Preclinical program was performed and very good results were achieved in models for multiple myeloma.Says will actively seek a collaboration partner for the development of tasquinimod within this indication.During 2016 orphan drug status applications for tasquinimod treatment of multiple myeloma are planned to be submitted to authorities in the EU and USA.Multiple myeloma is an incurable form of blood cancer where the plasma cells in the bone marrow grow uncontrollably while other blood forming cells such as white and red blood cells and blood platelets are suppressed.Says total market for multiple myeloma drugs amounted to 7.8 billion usd in 2013 (globaldata 2015).
Full Article

Active Biotech AB:Says Teva and Active Biotech announce discontinuation of higher doses of Laquinimod in two multiple sclerosis trials.Says ‍occurrence of cardiovascular events, none of which was fatal, in eight patients​.Says ‍both trials, concerto and arpeggio, are continuing lower-dose arms (0.6mg daily), and participants in trials will be provided with an update to confirm re-consent for participation​.
Full Article

Active Biotech AB:Says final results from Active biotech's 10tasq10 phase 3 study of tasquinimod presented at the ECC conference.Says final results show that tasquinimod treatment resulted in a prolonged radiographic progression free survival (rPFS), 7.0 vs. 4.4 months (central assessment) similar to an earlier Phase 2 study.Says the positive effect on rPFS did not translate into an improved OS (HR 1.097, 95 pct CI: 0.938-1.282).Tasquinimod safety was in general manageable and similar to what was observed during the Phase 2 study.
Full Article

Active Biotech AB:Says focuses the operations on the laquinimod project and adjusts the organization.Made a notification of planned redundancies of 47 of employees, which means a down-sizing of operations.Operating costs are expected to decrease to about 50 million Swedish crowns per year, from 2016.Says planned organizational adjustment leads to substantially reduced operating costs.
Full Article

Active Biotech AB:Active Biotech and Ipsen SA announce their decision to discontinue the development of Tasquinimod in prostate cancer.Efficacy results together with preliminary safety data do not support positive benefit risk balance.Full results will be presented at an upcoming scientific conference.
Full Article

Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products: